inclusion criteria: * laboratory confirmed sars-cov-2 infection, with positive molecular test results within the past 72 hours\* * aged \>=6 months \*\* * resident in the study area * the participant or caretaker is willing and able to give informed consent or assent with parent/guardian informed consent for participation in the study * agrees not to self-medicate with chloroquine, hydroxychloroquine or other antimalarials with potential anti-sars-cov-2 properties * not previously diagnosed with covid-19 * contactable by phone for follow-up permitting real-time, reliable information * uncomplicated malaria, defined as able to take oral medication * bodyweight ≥5kg * confirmed malaria infection by rdt (pldh) or microscopy

inclusion criteria: * laboratory confirmed sars-cov-2 infection, with positive molecular test results within the past 72 hours\* * aged \>=6 months \*\* * resident in the study area * the participant or caretaker is willing and able to give informed consent or assent with parent/guardian informed consent for participation in the study * agrees not to self-medicate with chloroquine, hydroxychloroquine or other antimalarials with potential anti-sars-cov-2 properties * not previously diagnosed with covid-19 * contactable by phone for follow-up permitting real-time, reliable information * uncomplicated malaria, defined as able to take oral medication * bodyweight ≥5kg * confirmed malaria infection by rdt (pldh) or microscopy

inclusion criteria: - laboratory confirmed sars-cov-2 infection, with positive molecular test results within the past 72 hours* - aged >=6 months ** - resident in the study area - the participant or caretaker is willing and able to give informed consent or assent with parent/guardian informed consent for participation in the study - agrees not to self-medicate with chloroquine, hydroxychloroquine or other antimalarials with potential anti-sars-cov-2 properties - not previously diagnosed with covid-19 - contactable by phone for follow-up permitting real-time, reliable information - uncomplicated malaria, defined as able to take oral medication - bodyweight ≥5kg - confirmed malaria infection by rdt (pldh) or microscopy

inclusion criteria: - laboratory confirmed sars-cov-2 infection, with positive molecular test results within the past 72 hours* - aged >=6 months ** - resident in the study area - the participant or caretaker is willing and able to give informed consent or assent with parent/guardian informed consent for participation in the study - agrees not to self-medicate with chloroquine, hydroxychloroquine or other antimalarials with potential anti-sars-cov-2 properties - not previously diagnosed with covid-19 - contactable by phone for follow-up permitting real-time, reliable information - uncomplicated malaria, defined as able to take oral medication - bodyweight ≥5kg - confirmed malaria infection by rdt (pldh) or microscopy